ASCO21: First-in-human administration of CEB-01, a novel drug delivery implant matrix, in patients with recurrent or locally advanced retroperitoneal soft tissue sarcoma (RPS) after surgery: Preliminary safety and pharmacokinetics report. …
The Cebiotex project started when 6-year-old Sara passed away after 4 years fighting child cancer. This experience motivated the founder Joan Bertran to investigate and develop new biomaterials that could bring medical solutions to paediatric and adult oncology, expanding to the health sector.
After three years of combined scientific work, Cebiotex was constituted in 2012 as a result of the interaction between researchers from the UPC and the HSJD. Our spin-off started its activity after closing the first funding round in 2015.
Our current mission is to provide solutions to patients with cancer, both paediatric and adult. Our future perspective is to also provide solutions to patients who suffer from infections or who need advanced therapies for marrow and cartilage regeneration, marrow injuries, etc.
Our first drug, CEB-01, meets an oncological and surgical need that has not yet been met by helping surgeons in their surgical oncology interventions.
Our objective is for CEB-01 to become part of the Standard of Care in surgical oncology.